Each year, approximately 1.5 million U.S. adults have a heart attack or stroke, resulting in approximately 30 deaths every hour and, for nonfatal events, often leading to long-term disability (1) . Overall, an estimated 14 million survivors of heart attacks and strokes are living in the United States (1) . In 2011, the U.S. Department of Health and Human Services, in collaboration with nonprofit and private organizations, launched Million Hearts (http://www.millionhearts.hhs.gov), an initiative focused on implementing clinical and communitylevel evidence-based strategies to reduce cardiovascular disease (CVD) risk factors and prevent a total of 1 million heart attacks and strokes during the 5-year period 2012-2016 (2, 3) . From 2005 From -2006 to the period with the most current data, analysis of the Million Hearts four "ABCS" clinical measures (for aspirin, blood pressure, cholesterol, and smoking) showed 1) no statistically significant change in the prevalence of aspirin use for secondary prevention (53.8% in 2009-2010), 2) an increase to 51.9% in the prevalence of blood pressure control (in 2011-2012), 3) an increase to 42.8% in the prevalence of cholesterol management (in 2011-2012), and 4) no statistically significant change in the prevalence of smoking assessment and treatment (22.2% in [2009] [2010] . In addition, analysis of two community-level indicators found 1) a decrease in current tobacco product smoking (including cigarette, cigar, or pipe use) prevalence to 25.1% in 2011-2012 and 2) minimal change in mean daily sodium intake (3,594 mg/day in [2009] [2010] . Although trends in some measures are encouraging, further reductions of CVD risk factors will be needed to meet Million Hearts goals by 2017.
Data Sources
Data from the National Health and Nutrition Examination Survey (NHANES*) for 2005-2012 were used to calculate prevalence estimates for managed low-density lipoprotein cholesterol (LDL-C † ) among hyperlipidemic adults aged ≥20 years and estimates for controlled blood pressure § among hypertensive adults aged ≥18 years. The 2005-2010 NHANES data were the most recent available to estimate the mean daily sodium intake (mg/day ¶ ) among adults aged ≥18 years. Data from the 2005-2010 National Ambulatory Medical Care Survey (NAMCS**) were combined into 2-year cycles to estimate the prevalence of office visits to primary care physicians and cardiologists where aspirin or other antiplatelet medication was prescribed to adults aged ≥18 years with ischemic vascular disease. † † Additionally, NAMCS data were used to estimate the prevalence of office visits where smoking treatment was prescribed among adults aged ≥18 years who were identified as were combined into 2-year cycles to estimate the prevalence of current tobacco product smoking*** among adults aged ≥18 years. This newly adopted measure of current tobacco smoking has been included because it measures all combustible tobacco product use, which is a major CVD risk factor (1) and not just cigarette use, as was the case with previous measures. Up to four survey cycles (2005-2006, 2007-2008, 2009-2010, and 2011-2012) were examined using sex-, age-, and race/ethnicity-adjusted linear trends analyses (p<0.05). Sex-, age-, and race/ethnicity-adjusted t-tests were used to examine 1) prevalence changes comparing the two most recent data cycles (p<0.05) and 2) differences between sex, age, and raceethnicity groups within the most recent data cycle (p<0.05).
ABCS Clinical Measures
In 2009-2010, prevalence of recommended aspirin use was greater among men (58.5%) than women (48.0%) and greater among non-Hispanic whites (55.7%) compared with Hispanics (43.6%) ( Table 1 (Table 1) . Additionally, the prevalence was higher among non-Hispanic whites (47.4%) compared with non-Hispanic blacks (35.5%) and Hispanics (23.0%). In 2009-2010, the prevalence of smoking assessment and treatment (e.g., cessation medication or counseling) was greater among adults aged 45-64 years (25.3%) compared with those aged 18-44 (20.0%) and ≥65 years (18.9%).
Community-Level Risk Factor Measures
Current tobacco product (cigarettes, cigars, or a pipe) smoking prevalence decreased from 28. Table 2) .
The Table 2 ).
Discussion
To reach the goal of preventing 1 million heart attacks and strokes during 2012-2016, Million Hearts set population-level goals of achieving ≥65% prevalence for each ABCS clinical measure as well as a 20% reduction in sodium intake (to approximately 2,900 mg/day) and a 10% reduction in current tobacco product smoking prevalence (to approximately 23.6%) (2) . A goal to decrease mean daily trans-fatty acid intake is still being promoted (e.g., by supporting ongoing efforts to remove artificial trans-fats from the food supply); however, regular measurement has been deemphasized because of the considerable recent decreases in trans-fat consumption (4) and the cost of regularly obtaining population estimates of consumption. Million Hearts has focused on improving performance in specific clinical and community-level CVD risk factors because interventions in these areas have been shown to be effective ways to greatly decrease CVD morbidity and mortality (2) .
Current estimates from 2005-2012 for certain Million Hearts measures serve as baseline values for achieving the initiative's 2017 goals. Additional progress needs to be made in all reported measures important to cardiovascular health, especially among those groups with the smallest prevalence of desired characteristics. For example, the most recently available data show that, compared with those aged ≥45 years, younger adults were more likely to have uncontrolled blood pressure and poorly managed cholesterol, and to smoke tobacco products; younger adults were less likely to receive smoking assessment and treatment, and had greater mean daily sodium intakes. These differences place younger adults at considerable risk Abbreviations: ABCS = aspirin use for secondary prevention, blood pressure control, cholesterol management, smoking assessment and treatment; CI = confidence interval. * Weighted, unadjusted estimates. † t-test for statistically significant differences among demographic subgroups, adjusted for sex, age group, and race/ethnicity, using linear/logistic regression. § Source: National Ambulatory Medical Care Survey (NAMCS). Includes office visits to primary care physicians and cardiologists by patients aged ≥18 years with ischemic vascular disease in which aspirin or other antiplatelet medications are prescribed. Excludes visits by patients with a contraindicated condition or medication and obstetric and gynecologic visits. ¶ Source: National Health and Nutrition Examination Survey (NHANES). Blood pressure (BP) control is defined as an average systolic BP <140 mmHg and an average diastolic BP <90 mmHg. Calculated among adults aged ≥18 years with hypertension. Hypertension defined as an average systolic BP ≥140 mmHg, or an average diastolic BP ≥90 mmHg, or self-reported current use of BP-lowering medication, defined as an answer of "yes" to the following questions: "Because of your high blood pressure/hypertension, have you ever been told to take prescribed medicine?" and "Are you currently taking medication to lower your blood pressure?" Excludes pregnant women. ** Source: NHANES. Cholesterol control is defined as a fasting low-density lipoprotein cholesterol (LDL-C) value among adults aged ≥20 years below the target levels (<100 mg/dL for the high risk group, <130 mg/dL for the intermediate risk group, and <160 mg/dL for the low risk group). Calculated among those with LDL-C dyslipidemia, defined using National Cholesterol Education Program's Adult Treatment Panel III risk categories based on the risk for developing coronary heart disease in the next 10 years. Additional information available at http://www.nhlbi.nih.gov/guidelines/cholesterol/ index.htm. Current use of cholesterol-lowering medication is defined as an answer of "yes" to the following questions: "To lower your blood cholesterol have you ever been told by a doctor or other health professional to take prescribed medicine?" and "Are you now following this advice to take prescribed medicine?" Excludes pregnant women. † † Source: NAMCS. Includes physician office visits by persons aged ≥18 years who screened positive for current tobacco use during which tobacco cessation counseling or cessation medications were provided. Additional stratification provided for adults aged 18-24 and 25-44 years because of higher prevalence of tobacco use among these age groups. † † † Current smokers were defined as those adults aged ≥18 years who had smoked at least 100 cigarettes in their lifetime and now smoke every day or some days. Additional information available at http://www.cdc.gov/nchs/nhis/ tobacco/tobacco_statistics.htm.
for developing CVD and suffering a CVD-related event during their lifetime; persons with two or more major CVD risk factors by age 50 years have more than 10 times the risk for developing atherosclerotic CVD compared with those who are free from major CVD risk factors at that age (5). The findings in this report are subject to at least seven limitations. First, new cholesterol management guidelines recently released by the American College of Cardiology (ACC) and American Heart Association (AHA) focus on providing treatment with appropriate types and doses of cholesterol-lowering medications (statins) rather than routine treatment to cholesterol targets (6) . The cholesterol management rates reported here are based on the previous guidelines in place when the data were collected and the initiative was launched. Second, debate continues over what population-level thresholds should be used to demonstrate adequate blood pressure control, particularly among older adults (7) . This report uses the thresholds recommended for the general population by the Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, because the recommendations remain endorsed by organizations including the ACC, AHA, and the National Institutes of Health and aligns What are the implications for public health practice?
Although trends in some measures are encouraging, additional efforts to reduce cardiovascular risk factors are needed to meet the 2017 Million Hearts goals.
with Healthy People 2020 measures. Third, response rates for the three different surveys ranged from 58.3% to 77.4%, and the results might be subject to nonresponse bias. Fourth, each survey used excludes certain population segments. For example, NHANES surveys include only the noninstitutionalized U.S. population and do not include military personnel. Fifth, one of the smoking cessation medications, bupropion, has multiple indications; however, all bupropion prescriptions were considered as cessation treatment, representing approximately 10% of all documented cessation interventions. Sixth, NAMCS-based visit estimates rely on health-care providers' intervention documentation, for which the quality might vary over time, thereby affecting trend analyses. Finally, the aspirin measure describes the health-care provider's recommended use of aspirin or other antiplatelet medication at a visit and not actual medication use; the indication for use is also not collected. Measures of patientreported aspirin use are being explored. Million Hearts strategies (2, 3, 8) that address these CVD risk factors include promoting use of standardized hypertension treatment protocols (9) , effective use of health information technology (2), and self-measured blood pressure monitoring Million Hearts community-level risk factors 
